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Background
Lung cancer mortality accounts for almost one third of all
cancer-related deaths and non-small-cell lung cancer
(NSCLC) represents the most frequent histotype [1]. The role
of cytotoxic chemotherapy (CTx) is limited, and the progno-
sis remains unsatisfactory with 5-year survival rates of only
15% for all stages. The median survival of locally advanced
and metastatic NSCLC does not exceed 18 months and 9
months respectively [2]. This is why the requirement for more
effective treatments with fewer side effects has provoked the
most recent interest in biological and clinical research.
The epidermal growth factor receptor (EGFR) is a tyro-
sine kinase (TK) receptor of the ErbB family, which
includes ErbB1 (HER-1 or EGFR), ErbB2 (HER-2/neu),
ErbB3 (HER-3) and ErbB4 (HER-4). EGFR, a 170-kDa
membrane-bound protein, encoded by 28 exons, located on
chromosome 7p12, as well as the other family members,
have an integral kinase activity and an extracellular ligand-
binding domain, a transmembrane region and a multifunc-
tional cytoplasmatic tail. The latter has an ATP-binding
site that allows the receptor autophosphorylation, which
enhances an enzymatic pathway, involved in the cellular
proliferation, angiogenesis and survival. The autophospho-
rylation is mediated by ligand binding, which causes
receptor dimerisation, both as homodimer and as het-
erodimer with other members of EGFR family, preferen-
tially with HER2. This process activates downstream sig-
nalling pathways, including the Ras/Raf/Mitogen-activat-
ed protein kinase (MAPK) pathway and the phosphatidyli-
nositol 3-kinase (PI3K)-Akt pathway, linked to cell prolif-
eration, transformation and survival (Fig. 1).
EGFR is over-expressed in 40%–80% of NSCLC
patients, suggesting that the activation of the EGFR signal
pathway represents one of the essential mechanisms of
tumorigenesis. This is correlated with disease progression,
lower response to standard therapy, development of resis-
tance to cytotoxic drugs and overall poor survival [3, 4].
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Abstract The medical treatment of non-small-cell lung
cancer (NSCLC) has progressively changed since the
introduction of “targeted therapy”. The development of
one of these molecular drug categories, e.g., the epidermal
growth factor receptor (EGFR) tyrosine-kinase (TK)
selective inhibitors, such as the orally active gefitinib and
erlotinib, offers an interesting new opportunity. The clini-
cal response rates obtained with their employment in uns-
elected patient populations only account for approximate-
ly 10%. Because of this, over the last two years numerous
studies have been performed in order to identify the
patient subsets that could better benefit from these agents.
Not only patient characteristics and clinical-pathological
features, such as never-smoking status, female gender,
East Asian origin, adenocarcinoma histology, bronchi-
oloalveolar subtype, but also molecular findings, such as
somatic mutations in the EGFR gene, emerge as potential-
ly useful prognostic and predictive factors in advanced
NSCLC. Further, specifically designed clinical trials are
still needed to completely clarify these and other open
issues that are reviewed in this paper, in order to clarify all
the interesting findings available in the clinical practice.
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The identification of small molecules able to inhibit
the TK activity of EGFR, by competing with ATP for the
ATP-binding site, stopping tumour cell growth by prevent-
ing the activation of EGFR, represents a new form of anti-
cancer treatment, aimed at the blockage of a special target.
Currently two of these agents have been approved by the
US Food and Drugs Administration (FDA): the orally
active gefitinib (Fig. 2) and erlotinib (Fig. 3).
After a long series of preclinical studies, these mole-
cules were first clinically tested in CT-refractory patients
(Table 1). Two phase II studies [5, 6] were conducted in
order to test the efficacy of gefitinib at two different doses:
the IDEAL-1 shows 18% partial response (PR), median
survival of 8 months in Japanese and European patients who
received one or two prior platinum-based CTx. The IDEAL-
2 shows 11% PR, median survival of 7 months in American
patients who had previously received two or more regimens
containing cisplatin or carboplatin and docetaxel. Disease
control (objective response and stable disease) was achieved
in approximately 50% of the patients in both trials, togeth-
er with symptom improvement.
Two subsequent randomised phase III trials [7, 8] were
conducted in previously untreated patients; a standard
platinum-based CTx was employed, with or without gefi-
tinib at two doses (INTACT-1, cisplatin and gemc-
itabine±gefitinib; INTACT-2, carboplatin and paclitax-
el±gefitinib). The results of both studies do not show any
differences in response rates, time to progression and sur-
vival with the addition of the targeted therapy to CTx.
Similar studies were conducted in order to evaluate the
efficacy of erlotinib at the dose of 150 mg: this molecule
was administered in previously treated patients in a phase
II trial [9], producing an objective response rate of 12%
and a median survival of 8 months. Two subsequent phase
III trials [10, 11] randomised patients in advanced stage to
receive as first-line treatment a platinum-based CTx, with
or without erlotinib (TALENT, cisplatin and gemc-
itabine±erlotinib; TRIBUTE, carboplatin and paclitax-
el±erlotinib). Both studies fail to demonstrate significant
clinical benefits in the experimental arm.
Two recent phase III studies focused on the efficacy of
EGFR TK inhibitors in comparison with placebo. In the
Canadian trial (BR. 21) patients were randomised to
receive erlotinib or placebo after first or second-line CTx
[12]. Statistically significant differences were observed for
overall survival and progression-free survival. A similar
study (ISEL) randomly assigned patients to receive gefi-
tinib or placebo, but it failed to show any advantage in sur-
Table 1 Drug-related non-haematological toxicities by worst com-
mon toxicity criteria (CTC) grade
Adverse event CTC grade  CTC grade 
1–2 3–4
Gefitinib, 250 mg/day, n=102
Diarrhoea 47% 1%
Rash 43% –
Acne 25% –
Dry skin 13% –
Nausea 12% 1%
Vomiting 11% 1%
Erlotinib, 150 mg/day, n=485
Rash 67% 8%
Diarrhoea 48% 6%
Anorexia 43% 9%
Fatigue 34% 18%
Dyspnoea 13% 28%
Nausea 30% 3%
Vomiting 21% 2%
Fig. 1 EGF receptor-signal transduction pathway
Fig. 3 Erlotinib
Fig. 2 Gefitinibvival [13]. This data led to consideration of a possible dif-
ference between these two molecules, although the results
of phase III studies differently designed could also be
taken into consideration.
Safety evaluation has been primarily based on the
results of trials in which patients received gefitinib or
erlotinib monotherapy. From all these trials, the toxicity
profile for both drugs is favourable.
No significant myelosuppression is observed. The most
common non-haematological toxicities by worst common
toxicity criteria grade reported at the recommended doses
of gefitinib and erlotinib are shown in Table 2. They are
diarrhoea, rash, dry skin, nausea and vomiting. Adverse
events reported to a lesser extent were pruritus, anorexia,
asthenia, weight loss, peripheral oedema, amblyopia, dys-
pnoea, conjunctivitis, vesiculobullous rash and mouth
ulceration. Liver function test abnormalities have occa-
sionally been observed. Cases of interstitial lung disease
have been reported in patients receiving gefitinib and
erlotinib with an overall incidence from all studies of
approximately 1% and 0.6%, respectively [14].
In this paper we have reviewed the current knowledge
and pointed out the future directions of the clinical utili-
sation of gefitinib and erlotinib in NSCLC.
Prognostic and predictive factors
Clinical and pathological features
The overall unexpected low percentage of clinical
response has been investigated in order to identify clinico-
biological characteristics potentially related to a selective
activity of these agents in patient subgroups.
Analysis of data from the principal trials show that
response to TK inhibitors does not correlate with EGFR
overexpression, but instead, well defined patient and tumour
characteristics, such as female gender, non-smoking status,
East Asian ethnicity, adenocarcinoma histology and bron-
chioloalveolar subtype, represented the features most likely
associated with treatment response.
In the IDEAL 1 trial, the response rate is higher in
Japanese patients (27.5% vs. 10.4%, p=0.0023), is 2.5 times
higher in women than in men and 3.5 times higher in ade-
nocarcinoma than in other histologies [5]. In the IDEAL 2
trial, the response rate is 19% in the female population and
3% in the male, and 13% for adenocarcinoma vs. other his-
tologies [6]. The Expanded Assess Program conducted at the
Memorial Sloan-Kettering Cancer Center confirms better
responses in women (19% vs. 8%, p=0.14) and in adenocar-
cinoma (19% vs. 0%, p=0.004), particularly in bronchi-
oloalveolar carcinoma (38% vs. 14%, p=0.001), and finds a
significantly higher response rate in never-smoker patients
vs. former or current smokers (36% vs. 8%, p=0.001) [15].
Several smaller trials confirm the above-mentioned
results, and contribute to better define the characteristics
of the patient populations more responsive to this form of
anticancer treatment [16].
EGFR mutations
Molecular mechanisms underlying TK inhibitor sensitivi-
ty have been recently identified, with the majority of high-
Table 2 Clinical response rate and median survival obtained with gefitinib and erlotinib in NSCLC treatment, investigated in phase II and
III clinical trials
Trial, year Phase Treatment Number  Response rate  Median survival
of pts (%) (months)
IDEAL 1, 2003 [5] II Gefitinib (250 or 500 mg*) 210 18 8
IDEAL 2, 2003 [6] II Gefitinib (250 or 500 mg*) 216 11 7
INTACT 1, 2004 [7] III G/C+gefitinib (250 or 500 mg*) 730 50 10
vs. G/C+placebo 363 45 11
INTACT 2, 2004 [8] III C/P+gefitinib (250 or 500 mg*) 692 30 9
vs. C/P+placebo 345 29 10
TALENT , 2004 [10] III G/C+erlotinib (150 mg) 586 31 10
vs. G/C+placebo 586 30 10
TRIBUTE, 2005 [11] III C/P+erlotinib (150 mg) 539 21 11
vs. C/P+placebo 540 19 10
BR.21, 2005 [12] III Erlotinib (150 mg) 488 9 7
vs. placebo 243 <1 5
ISEL, 2005 [13] III Gefitinib (250 mg) 1129 8 5
vs. placebo 563 1 5
G/C, gemcitabine/cisplatin; C/P, carboplatin/paclitaxel; pts, patients
*The trial randomisation utilised two dosages of gefitinib, 250 and 500 mg, but no differences were found in terms of efficacy
K. Bencardino et al.: EGFRr TK inhibitors in non-small-cell lung cancer 5
IM6 K. Bencardino et al.: EGFRr TK inhibitors in non-small-cell lung cancer
ly responsive tumours containing somatic mutations of the
EGFR gene. Several studies with different design have
focused on the possible predictive value of EGFR muta-
tions in NSCLC (Table 3).
Mutations in the EGFR TK domain are found mostly in
subjects who respond to gefitinib, as reported in the first
three studies conducted in 2004 [17–19]. The same muta-
tions are more frequent in women, in adenocarcinoma, in
non-smokers and in Japanese subjects, all with a statistical
significance [17]. These were clustered in exons 18, 19 and
21 and were either small in-frame deletion (746–750, adja-
cent to K745: ELREA aminoacids) or heterozygous mis-
sense mutations (mainly L858R adjacent to the DFG motif
in the COOH-terminal lobe in the activation loop of the
kinase) around the ATP binding pocket. Pooled data from
these three studies show that 25 of 31 (81%) patients with
partial response or marked clinical improvement have an
EGFR mutation, vs. none of 29 specimens from refractory
patients (p=0.0001).
Several other studies investigate the role of these muta-
tions in the treatment of NSCLC with EGFR TK inhibitors,
demonstrating a statistically significant correlation between
the response to gefitinib and erlotinib and the presence of the
biological data, but this correspondence is not always 100%
[20–28] (Table 3). In fact objective responses are also
described in patients with a wild-type EGFR, although with
a lower percentage, ranging from 10% to 13% [21–23].
The probability of EGFR TK inhibitor efficacy not only
increases with the presence of a mutational status, which
results in the principal feature linked with response, but
also correlates with female gender, non-smoker status,
Asiatic origin and adenocarcinoma histology [21–28].
Other characteristics also influence tumour response, such
as a greater number of prior CTx lines, or a younger age,
but they are reported in only a few papers [21, 22].
Furthermore, patients with EGFR mutations survive for a
longer period than those without the mutations after initia-
tion of gefitinib treatment (p=0.0053). A specific mutation
(del746–750) is found to be superior to other (L858R)
mutations for the prediction of response to gefitinib [23].
The same advantage in terms of time to progression (21.7
vs. 1.8 months; p<0.001) and survival (30.5 vs. 6.6 months;
p<0.001) is demonstrated in the Korean study [25].
The treatment with gefitinib of only Japanese patients
after a first recurrence shows 53% objective responses, a
median time to progression of 5 months, and a median
survival of 16 months. Thirty-nine out of 66 patients had
EGFR mutations, and their response rate (82% vs. 11%;
p<0.0001), time to progression (12.6 vs. 1.7 months;
p<0.0001) and overall survival (20.4 vs. 6.9 months;
p=0.0001) are higher in comparison to the wild-type
patients [24]. These data once again show the higher sen-
sitivity of the Asiatic population to EGFR-TK inhibitors.
Considering the importance of this data, the contribu-
tion of molecular alterations in EGFR to response and sur-
vival was determined in the patients treated inside the
IDEAL and INTACT gefitinib trials, retrospectively.
EGFR mutations were found in 14 out of 79 cases from
the IDEAL studies’ available tumour samples, and in 32
out of 312 cases from the INTACT trials, including amino
acid substitutions, in-frame deletions clustered around the
ATP binding pocket. These mutations result more fre-
quently in adenocarcinomas than in tumours with other
histologies (17% vs. 5%; p=0.0001), in women than men
(19%  vs. 9%;  p=0.006), in non-smokers than smokers
(26% vs. 8%; p=0.0004) and in Asians than non-Asians
(19% vs. 11%; p=0.346). Patients whose tumours have an
EGFR mutation show a better response to gefitinib, with
an overall response of 46% vs. 10% (p=0.005). Median
time to progression for mutation positive cases was longer
Table 3 EGFR gene mutations and clinical response rate to EGFR TK inhibitors
Author, year Inhibitor Number of Responder pts  Number of    p value
pts (number) responder pts
with EGFR gene
mutation (%)
Paez et al., 2004 [17] Gefitinib 9 5 5 (100) 0.0027
Lynch et al., 2004 [18] Gefitinib 16 9 8 (88) 0.001
Pao et al., 2004 [19] Gefitinib 24 12 9 (75) 0.001
Erlotinib 36 10 8 (80) 0.001
Kondo et al., 2005 [20] Gefitinib 12 4 4 (100) NA
Rosell et al., 2005 [21] Gefitinib 34 10 7 (70) 0.0003
Taron et al., 2005 [22] Gefitinib 68 22 16 (73) 0.0001
Mitsudomi et al., 2005 [23] Gefitinib 59 26 24 (96) 0.0001
Takano et al., 2005 [24] Gefitinib 66 35 32 (91) 0.0001
Han et al., 2005 [25] Gefitinib 90 21 11 (52) 0.001
Tomizawa et al., 2005 [27] Gefitinib 20 14 11 (79) 0.0022
Niho et al., 2005 [58] Gefitinib 13 4 4 (100) NA
EGFR, epidermal growth factor receptor; TK, tyrosine kinase; pts, patients; NA, not assessed(116 days vs. 57 days), but no impact was detected on
overall survival. Molecular analysis reveals that 13 of 18
EGFR mutation carriers (72%) respond to chemotherapy
plus gefitinib, compared to 84 of 152 mutation-negative
cases (55%), but this difference does not achieve statistical
significance (p=0.2) [26].
The majority of these studies were conducted testing
the activity of gefitinib, but similar data were obtained
with erlotinib. In particular Eberhard et al. analysed the
mutational status and its impact on patients treated in the
TRIBUTE trial [28]. Tumour EGFR mutations were iden-
tified in 29 of 228 subjects (12%) and among them 17%
were never smokers. The overall response rate improved in
patients treated with erlotinib and CTx, who express
EGFR mutations in comparison with the wild-type
tumours, and both time to progression and survival are
affected by EGFR mutational status. Moreover, among
EGFR mutants, overall response rate is higher in the
erlotinib plus CTx arm compared to CTx alone, but this
does not reach statistical significance.
Finally, a recent study shows not only that EGFR muta-
tions are statistically associated with Asian ethnicity and
never-smoker status, but also that patients with EGFR exon
19 deletions have significantly longer median survival than
patients with EGFR L858R mutation (34 vs. 8 months,
p=0.01) after treatment with gefitinib or erlotinib [29].
These findings suggest that testing for EGFR mutations
could effectively be not only of predictive but also of prog-
nostic importance for patients with NSCLC, but the relevance
of such testing in selecting patients for EGFR TK inhibitor
therapy remains incompletely defined, as these data emerge
from studies limited by unspecific end points and design [30].
Another unclarified point is related to the method of
assessing mutations, which was different in several trials,
in the absence of a standard method. To this end, recent
investigations concern the validation of novel assessments,
such as a dual technical approach: direct sequencing of
polymerase chain reaction (PCR) products and PCR sin-
gle-strand conformation (SSC) polymorphism (SSCP)
analysis. The SSCP analysis results in more sensitive than
direct sequencing of PCR products, and consists of a rapid
and reliable method for the screening of EGFR kinase
domain mutations [31]. Evaluations of newer techniques,
like mutant-enriched PCR and DNA endonuclease SUR-
VEYOR, are ongoing, resulting in valuable methods in
collecting preliminary data [32, 33].
EGFR amplifications
The role of EGFR amplification in the relationship with
NSCLC prognosis and clinical response to the treatment
with small molecules like TK inhibitors is still controversial
(Table 4).
Hirsch et al. first report that EGFR gene copy number
correlates with EGFR protein expression, but not with
prognosis [34]. Considering these data, the relationship
among EGFR gene copy number, EGFR protein expres-
sion and EGFR mutations (evaluated by fluorescence in
situ hybridisation (FISH) and immunohistochemistry) was
further investigated in 102 NSCLC patients, treated with
gefitinib. EGFR gene amplification and high protein
expression are significantly associated with a better clini-
cal response, disease control rate, time to progression and
survival, while EGFR mutations correlate with clinical
response and time to progression. In multivariate analysis
only the EGFR amplification is significantly associated
with a better survival [35]. The same statistically signifi-
cant benefits in terms of response rate and time to pro-
gression are reported in a Japanese study that also
observed more frequent EGFR gene amplification in
patients with EGFR mutations than in patients with wild-
type EGFR (p=0.014) [24].
Several other studies suggest the importance of the
amplification for the activation of the EGFR signalling
pathway, particularly when both gene amplification and
EGFR mutation are found in the same tumour, reaching a
response rate to gefitinib of 100% in the trial conducted by
Taron et al. [20, 22, 24, 26]. Nevertheless the latter also
showed a response rate of 45% in the patients with ampli-
fied EGFR in contrast with 89% of patients with EGFR
mutations (p=0.02). From these data it is difficult to deter-
mine the extent to which EGFR amplification in the
absence of mutations is predictive of response [22].
Finally, the retrospective study on the tumour specimens
collected in the IDEAL and the INTACT trials included not
only the EGFR mutation analysis but also the EGFR gene
amplification analysis by PCR. Amplification of EGFR
locus was observed in 7 of 90 IDEAL cases (8%) and in 33
of 453 INTACT cases (7%). There is no significant increase
in the prevalence of EGFR amplification in cases with clin-
ical features that are characteristic of strong responses to
gefitinib. In tumours analysed for both mutations and
amplification of EGFR, 6 of 10 patients (60%) with either
genetic abnormalities had a response to gefitinib, compared
with 5 of 52 patients (10%) with neither amplification nor
mutations (p=0.0011), supporting the hypothesis that genet-
ic lesions in EGFR are critical in defining TK inhibitors
susceptible subtypes of NSCLC [26].
On the contrary, Endo et al. surprisingly find that EGFR
amplification does not correlate with EGFR mutation status,
either with any of the clinico-pathological features or with
overall survival. The authors also show a high sensitivity of
TaqMan PCR to detect the mutation status [36].
On the basis of these contradictory results it is actually
very difficult to give an exact definition of the role of EGFR
amplification as prognostic and predictive factors, and even
more difficult to clearly understand the relationship between
EGFR mutations and EGFR gene amplification [37].
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While the mutational status seems to be important in deter-
mining the clinical response to EGFR TK-inhibitors,
recent evidence suggests that genes implicated in the
downstream of EGFR signalling are related not only to
cancer pathogenesis but also to the clinical response to
these molecular drugs.
The EGFR-dependent activation of the Ras/Raf/MAPK
and PI3/Akt pathways may be involved in the sensitivity to
EGFR TK inhibitors because of their role in cell prolifera-
tion and survival.
In this field, the presence of Akt in its active phospho-
rylated status (p-Akt) is associated not only with a better
response to gefitinib (p=0.003), disease control rate
(p<0.001) and time to progression (p=0.004), but also with
female gender (p<0.001), never-smoking status (p=0.004)
and bronchioloalveolar carcinoma histology (p=0.034). No
correlation is found with p-MAPK [38].
On the contrary, no significant correlation between
EGFR mutation and expression of p-Akt or p-Erk emerges
in another study [25].
ErbB signalling pathways also include downstream
GTPases encoded by Ras genes. K-ras mutations occur in
10%–30% of NSCLC cases, especially in codons 12 and
13 encoded by exon 2, showing a strong association with
smoking history and with poor prognosis [39]. Recent
studies demonstrate that EGFR and K-ras mutations are
mutually exclusive [40]. In fact, when the EGFR signal
pathway is activated by the genetic alteration of EGFR, the
mutation of Ras may not be necessary for the signal trans-
duction, as Ras is also one of the downstream molecules in
this pathway [20, 27]. The Italian investigation into the
relationship between EGFR and K-ras mutations in 860
NSCLC patients reports this data: all of the tumours affect-
ed by mutated EGFR are found to be negative for K-ras
mutations, whereas tumours negative for EGFR mutations
show a K-ras mutation in 32% of cases (p=0.000001) [31].
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In the TRIBUTE trial, K-ras mutations are detected in 21%
of tumours, and are associated with significantly decreased
time to progression and survival in patients treated with
erlotinib and chemotherapy [28]. Mutations in K-ras are found
more frequently in patients who develop disease progression
with either gefitinib or erlotinib [41]. Braf mutation is uncom-
mon both in Caucasian and in Japanese NSCLC patients [42,
43], and at the moment no data is available on its role.
From these studies in particular, a molecular aetiology-
and pathogenesis-related difference emerges: NSCLC aris-
ing in smokers seem to have a dissimilar spectrum of mol-
ecular alterations than those seen in non-smokers, as the
basis of their opposite prognosis and responsiveness to
EGFR TK inhibitors. In fact the presence of a K-ras muta-
tion, very frequent in smokers, could likely constitute a
useful marker for selecting those patients who will not
benefit from anti-EGFR therapy.
The relationship between somatic mutations of EGFR
and K-ras genes and DNA methylation of tumour suppres-
sor genes has been recently investigated, and a specific
interaction of genetic and epigenetic changes in the
tumorigenesis of NSCLC is identified [44]. Nowadays the
microarray analysis could represent a potentially useful
approach to better define the complexity of NSCLC car-
cinogenesis, including the molecular pathways that could
be associated with smoking habits and gender [45].
Finally, abnormal PI3K/Akt and Ras/Erk pathways seem
to be correlated with tumour insensitivity to receptor block-
ade, and considering this information, the combination treat-
ment of TK inhibitors and inhibitors of the PI3K/Akt and
Ras/Erk pathways may provide a successful strategy [46].
Other members of the EGFR family
Because of the complex crosstalk among the EGFR fami-
ly members, the TK inhibitor sensitivity could be related
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Table 4 EGFR amplification and clinical efficacy of gefitinib
Author, Number of  Number of pts  Response rate (%)    Time to Overall survival
year pts with EGFR in pts progression (months) in pts
amplification with FISH+ vs. (months) in pts with FISH+ vs.
FISH– with FISH+ vs. FISH–
FISH–
Cappuzzo et al., 2005 [35] 102 33 36 vs. 3, p=0.001 9.0 vs. 2.5, p=0.001 18.7 vs. 7, p=0.03
Kondo et al., 2005 [20] 12 2 NA NA NA
Takano et al., 2005 [24] 66 29 72 vs. 38, p=0.005 9.4 vs. 2.6, p=0.038 NA
Taron et al., 2005 [22] – 28 45 (FISH – NA) NA NA
Endo et al., 2005 [36] 27 4 NA NA No correlation
Bell et al., 2005 [26] 90 7 29 vs. 15, NA NA NA
Pts, patients; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridisationnot only to the EGFR presence, but also to the influence of
HER2 and HER3.
Preclinical data indicate that HER2, a member of the
EGFR family, could enhance TK inhibitor sensitivity.
EGFR family members, in fact, exist as monomers and the
monomeric receptors dimerise and become functionally
active after binding to the appropriate ligand; HER2 rep-
resents the preferred EGFR partner.
Independent of the method for EGFR assessment,
increased copy numbers of the HER2 gene enhance sensi-
tivity to gefitinib in patients with EGFR-positive tumours,
while mutations in the TK domain of the HER2 gene seem
to be infrequent and not clinically relevant. Patients with
HER2 high copy number (22.8%), detected by FISH, show
significantly better objective responses, disease control rate
and time to progression compared with patients with HER2
FISH-negative. Also, HER2 protein expression, tested by
immunohistochemistry, shows positive results in only 7%
of patients, and no HER2 mutations in exon 20 are found.
HER2 gene gain is significantly associated with EGFR gene
gain (p=0.004) and with EGFR gene mutations (p=0.003).
Patients with HER2 FISH-positive tumours with an
increased expression of EGFR protein, gene gain or EGFR
mutations have a significantly better clinical outcome than
patients negative for both receptors. On the contrary, in the
absence of EGFR mutations, the outcome of HER2-positive
patients is the same as the outcome of patients negative for
both receptors, which is the worst scenario for all the clini-
cal end points [47].
These data suggest a strong rationale to explore the
association of TK inhibitors and anti-HER2 agents,
emphasising their probable synergistic effects.
The correlation between EGFR and HER2 was also
studied, with controversial results. Neither mutation nor
expression of EGFR and HER2 are significantly related to
the prognosis. However, the number of HER2 mutated
patients was too small to accurately determine prognostic
association. Despite this limitation, an interesting relation-
ship emerges: EGFR overexpression results more fre-
quently in tumours with EGFR mutations (p=0.0059) [48].
A series of patients treated with gefitinib were evaluat-
ed for HER3 genomic gain by FISH. HER3 FISH-positive
pattern is significantly associated with female gender and
never smoking history, but this gene does not emerge as a
marker of response or resistance to TK inhibitors.
These data suggest a possible association between the
activation of these pathways and the presence of EGFR
mutations [49].
Acquired resistance to EGFR TK inhibitors
A substantial proportion of NSCLC patients treated with
gefitinib and erlotinib will ultimately develop a disease
relapse. The mechanism of such acquired drug resistance
remains practically unknown.
First, a secondary mutation in exon 20, leading to a sub-
stitution of methionine for threonine at position 790
(T790M) in the kinase domain, is reported in 2 of 5 patients
with acquired resistance to gefitinib or erlotinib [50].
An interesting case report describes the same mutation
associated with gefitinib resistance [51]: a 71-year-old
smoker, with lung adenocarcinoma resistant to CTx, had a
complete remission after treatment with gefitinib. After 24
months of therapy, the tumour recurred. Exons 18–21 of the
EGFR gene were sequenced from DNA isolated from both
the original diagnostic biopsy and the specimen obtained at
the relapse: while a small deletion mutation (delL747-S752)
was detected in both the biopsies, the presence of a second
point mutation, resulting in threonine-to-methionine amino
acid change at position 790 of EGFR (T790M), was detect-
ed only in the relapse specimen. The delL747-S752 belongs
to the mutations described above associated with gefitinib
responsiveness, and this report confirms these data. The
appearance of a second mutation represents a mechanism of
resistance: in fact the authors demonstrate that the insertion
of T790M into test cells renders them resistant to gefitinib
in vitro. They also find that when test cells transfected with
both mutations are treated with other EGFR inhibitors, such
as AG1478, cetuximab, erlotinib or CL-387,785, no objec-
tive response is obtained using the first three agents, while
the fourth is effective. The sensitivity of the delL747-
S752+T790M construct to the anilinoquinazoline CL-
387,785 might be explained either by its altered binding to
the kinase domain or its covalent binding to EGFR. These
data support clinical investigations of compounds similar to
CL-387,785 in order to identify optimal treatment strategy
for patients with resistance to EGFR inhibitor therapy
caused by T790M or other mutations [52]. A phase I dose
escalation study was conducted in Japanese patients in order
to test the efficacy of EKB-569, an oral EGFR inhibitor.
Preliminary data were recently published that show
that this agent has clinical activity in 2 patients with
advanced NSCLC with EGFR mutations and acquired
gefitinib resistance [53]. Finally, a recent retrospective
analysis of IDEAL trial specimens does not find any
T790M mutations in the tumours analysed [26].
Preclinical studies are ongoing not only to investigate
the biological mechanisms of resistance to EGFR TK
inhibitors in greater depth, but also to identify new agents
potentially able to overcome these phenomena [54, 55].
Timing of treatment with EGFR TK inhibitors
Several case reports are published in which EGFR TK
inhibitors are utilised upfront in patients with EGFR muta-
tions, and who are not eligible for a standard cytotoxic
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IMCTx [56]. These reports raise the question about the possi-
ble role of these agents as first-line therapy, and clinical
studies were conducted.
A phase II study of gefitinib as first-line treatment in
36 never-smoking patients was conducted in South Korea,
obtaining a response rate of 69% [57].
Another recent phase II study investigated the role of gefi-
tinib as first-line treatment in 40 eligible patients with
advanced NSCLC. In case of absence of tumour reduction
within 4 weeks or partial response within 8 weeks, the treat-
ment was interrupted, shifting to a platinum-based CTx. The
response rate was 30%, median survival time was 13.9
months and 4 patients developed a grade 5 interstitial lung
disease (10%). The response rate was statistically correlated
with adenocarcinoma histology (p=0.0048), female gender
(p=0.0050) and non-smoking status (p=0.0048). Tumour
samples were available for 13 patients (4 partial response, 6
stable disease and 3 progressive disease): EGFR mutations
were detected in 4 responder patients. The response rate of
the second line treatment was 30%, and it does not seem to be
adversely affected by pre-treatment with gefitinib [58].
Nowadays a key question about the use of EGFR TK
inhibitors in NSCLC is the rationale of their employment as
first-line treatment of advanced disease as well as neoadjuvant
or adjuvant treatment in those patients whose tumours have
EGFR mutations. In fact, the real impact of EGFR mutations
in making a therapeutic decision has not been well defined
because this target included the majority but not all respon-
ders, as has been revealed by the above-mentioned studies.
To date, no conclusive data are available from large,
prospective clinical trials evaluating these agents in earlier
treatment setting, and the availability of such biologic
drugs approved for the treatment of recurrent disease
selected patients.
Conclusions and open issues
During recent years, the development of targeted anti-
cancer therapy has become more promising than the opti-
misation of medical treatment with conventional anti-
cancer agents. In NSCLC, the targeting of EGFR TK, by
the small molecules gefitinib and erlotinib, has led to more
options in the management of patients with advanced dis-
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ease. The two drugs followed the same development pro-
cedure and, in spite of the large number of studies per-
formed to date, further research is still warranted to define
the ultimate clinical role of these agents.
In the field of prognostic and predictive factors that
will aid a clinically useful patient selection, it is necessary
to initiate large and well designed clinical trials with
EGFR TK inhibitors in different regions of the world, and
to focus on patient subsets characterised by specific clini-
cal and histopathological features.
Furthermore, our understanding of the molecular profile
in a tumour that may predict clinical response remains naïve,
and as the molecular heterogeneity of NSCLC becomes
more apparent, it is necessary to direct the research to iden-
tify the biomarkers that will indicate which patients are most
likely to experience therapeutic benefit. To this end it is
essential to incorporate the EGFR mutational profile and the
characterisation of the genes involved in the EGFR sig-
nalling, into specifically designed clinical trials. This also
means the urgent need for a careful standardisation of labo-
ratory methods for molecular marker characterisation.
Preclinical studies continue to be important, in particu-
lar to better define the potential role of the association
between different EGFR family members as well as to elu-
cidate the mechanisms of resistance to EGFR inhibitors
(and the possible strategies to overcome it).
At the same time, efforts should be directed to a better
understanding of useful strategies for associating these
agents with conventional CTx, also taking into account
that no exhaustive data is available on the possible effect
of CTx on EGFR expression or mutations.
Future research should also involve the identification
of the phase of disease in which these agents can be best
employed (such as the neoadjuvant and the adjuvant set-
ting), together with the validation of new surrogate mark-
ers of clinical response to these drugs. In fact, the effect of
molecular agents on tumour cells seems to be cytostatic
rather than cytotoxic so that the standard methodology
utilised for the assessment of efficacy in clinical cancer
research may not be the best one to test for the efficacy
evaluation of the targeted therapy.
In conclusion, EGFR TK inhibitors are promising anti-
cancer agents, but all the questions mentioned above have
not been completely answered by the relatively high number
of studies conducted to date (Table 5). Hence, designing spe-
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Table 5 Open issues about EGFR TK inhibitors employment in the treatment of NSCLC
Identification and validation of clinical and biological prognostic/predictive factors
Definition of standard methods for molecular target characterisation
Importance of the relationship among different EGFR family members
Better comprehension of the mechanisms of resistance and their possible treatment
Role of the association with conventional chemotherapy
Utilisation as neoadjuvant, adjuvant and first-line treatment
Specifically designed clinical trials including new surrogate end points, conducted in selected patient populationscific clinical trials to further investigate the activity of this
drug class and optimise their use in prospectively defined
patient populations are critical challenges to the final success
of this therapeutic approach. Only in this way, within the
next few years, will we find out whether we can make a real
paradigm shift in the treatment of NSCLC by translating all
the basic scientific progress into clinical practice.
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